The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
about
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesAdverse Effects of GLP-1 Receptor AgonistsIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseDivergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaIncretin-based therapies in prediabetes: Current evidence and future perspectivesChronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic conditionGPR40 modulators: new kid on the blockGlucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic TissuesProglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in RatsActing on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPERNo evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cellsA critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Interpreting adverse signals in diabetes drug development programs.Incretin therapy and islet pathology: a time for caution.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Do GLP-1-based therapies increase cancer risk?Pathogenesis of pancreatic cancer: lessons from animal models.Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.The regulation of pre- and post-maturational plasticity of mammalian islet cell mass.Incretins: their physiology and application in the treatment of diabetes mellitus.Antihyperglycaemic therapies and cancer risk.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.An updated review on cancer risk associated with incretin mimetics and enhancers.Safety of antidiabetes medications: An update.Adverse Effects Associated With Newer Diabetes Therapies.GLP-1 based therapies: clinical implications for gastroenterologists.Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
P2860
Q24568148-48CB5409-93B9-4BC5-ACEF-F59244FAA1FFQ26801346-0947FC7A-65C9-4967-AF8C-2BCD1F69DE53Q26827183-325AAC8F-D9BC-4D9A-B2A0-8EFADF7B71BFQ34041974-1D9486BE-C5E3-4ED8-8FBD-FCA1E5D81546Q34699191-90D988CD-7996-4F2C-8706-9CEFF5FAF8FBQ34780873-B8356972-A2C4-4CCE-BD62-3BF183F30EACQ35022184-79AE1EC0-A5EE-4E29-BB47-9E14DC2F4FC4Q35184904-9055A439-01F6-4BBE-A59E-EE96851CB77EQ36560325-8F8B4BB5-724A-4C6E-A4E4-1F3A48BA02F8Q36665328-11AC6E08-5821-4A84-A0F0-0A0E964E163CQ36763274-4748D1A9-5904-460D-AD33-BC9539C3FE64Q36800401-52091BC1-FAE1-4CF9-BCA9-5D2D51A5D7B9Q36845768-DA79FA25-36B2-4972-8777-0880F159FF77Q36930354-F4F4A076-48BB-4651-BCD9-479521F83C04Q36942123-21AADC0C-5E5F-4EED-B22B-7DD3F6896071Q36942266-D1551D77-A9DD-4CBA-A947-9953F4C7E0B0Q37015080-E559F9B2-2751-419D-9ACA-8E0E55DE0B9CQ37193295-20337C78-5ED7-47E3-8356-D2513B387C5EQ37402786-FDF3B54E-6856-407A-9224-652BCA760D6AQ37476451-DDC7506E-9A5A-48F0-AB2D-A057C1E7DE76Q37517909-794E21C9-D72F-4F73-A343-F1624DE5B4A1Q37577143-51692A1C-1537-4B5D-81C0-7007B23B1F00Q37589374-9E641AAC-FB9A-4EDE-B2D9-C6668A5F76F4Q37659673-23D5F9E3-482C-494C-A496-F427B6DAD7E3Q37660923-73947B3E-ACD2-4930-852F-3EDF0B947AF5Q38055195-5BC05186-B856-49D9-A7ED-535C4E7E0722Q38101993-DC84BED1-FA36-4B4B-AECB-2030B7508446Q38104338-B8C61DE9-9733-490B-8734-715A7754369AQ38126945-BD4D8146-9F49-4F27-BCFE-2B4FB90AA211Q38211528-452C5B55-5785-4B28-9DF8-CBE1AE753129Q38225693-2CCF41D6-B2CC-4357-B34B-020411CC5F8AQ38250719-89D2991C-77DA-49ED-8D88-08B3CDE33FBEQ38255715-FEDA46B7-1B64-47F7-AEB3-6DB07D392182Q38264360-A71C6D7B-E26A-4DD8-901C-F3F51E26A03CQ38286444-A48642B1-8EB4-4099-9657-7F33C862BCC3Q38388920-43F53FA9-B524-4690-88D7-C0428EB67138Q38395221-A764E112-D680-4154-8FD5-CEAA9BAF9BA2Q38546214-35D76A98-67F9-4535-AC5B-AAF90834EFA0Q38703292-2BE7F214-71DD-4E45-A6FB-D3A3343BFD27Q38997962-903E0AFF-55A1-41E0-9F98-495364CFC48E
P2860
The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The human GLP-1 analog liraglu ...... atic changes in three species.
@ast
The human GLP-1 analog liraglu ...... atic changes in three species.
@en
type
label
The human GLP-1 analog liraglu ...... atic changes in three species.
@ast
The human GLP-1 analog liraglu ...... atic changes in three species.
@en
prefLabel
The human GLP-1 analog liraglu ...... atic changes in three species.
@ast
The human GLP-1 analog liraglu ...... atic changes in three species.
@en
P2093
P2860
P356
P1433
P1476
The human GLP-1 analog liraglu ...... eatic changes in three species
@en
P2093
Anne-Marie Mølck
Lars W Madsen
Niels C B Nyborg
P2860
P304
P356
10.2337/DB11-0936
P407
P577
2012-02-14T00:00:00Z